SECURITIES AND FUTURES ACT (CAP. 289) SECURITIES AND FUTURES (DISCLOSURE OF INTERESTS) REGULATIONS 2012

NOTIFICATION FORM FOR DIRECTOR/CHIEF EXECUTIVE OFFICER IN RESPECT OF INTERESTS IN SECURITIES

FORM

1
(Electronic Format)

Explanatory Notes

- 1. Please read the explanatory notes carefully before completing this notification form.
- 2. This form is for a Director/Chief Executive Officer ("CEO") to give notice of his interests in the securities of the Listed Issuer under section 133, 137N or 137Y of the Securities and Futures Act (Cap. 289) (the "SFA"). Please note that the requirement to disclose interests in participatory interests applies **only** to a director and where the Listed Issuer is a Singapore-incorporated company.
- 3. This electronic Form 1 and a separate Form C, containing the particulars and contact details of the Director/CEO, must be completed by the Director/CEO or a person duly authorised by him to do so. The person so authorised should maintain records of information furnished to him by the Director/CEO.
- 4. This form and Form C, are to be completed electronically and sent to the Listed Issuer via an electronic medium such as an e-mail attachment. The Listed Issuer will attach both forms to the prescribed SGXNet announcement template for dissemination as required under section 137G(1), 137R(1) or 137ZC(1) of the SFA, as the case may be. While Form C will be attached to the announcement template, it will not be disseminated to the public and is made available only to the Monetary Authority of Singapore (the "Authority").
- 5. A single form may be used by a Director/CEO for more than one transaction resulting in notifiable obligations which occur within the same notifiable period (i.e. within two business days of/of becoming aware of, the earliest transaction). There must be no netting-off of two or more notifiable transactions even if they occur within the same day.
- 6. All applicable parts of the notification form must be completed. If there is insufficient space for your answers, please include attachment(s) by clicking on the paper clip icon on the bottom left-hand corner or in item 3 of Part II or item 10 of Part III. The total file size for all attachment(s) should not exceed 1MB.
- 7. Except for item 4 of Part III, please select only one option from the relevant check boxes.
- 8. Please note that submission of any false or misleading information is an offence under Part VII of the SFA.
- 9. In this form, the term "Listed Issuer" refers to -
 - (a) a company incorporated in Singapore any or all of the shares in which are listed for quotation on the official list of a securities exchange;
 - (b) a corporation (not being a company incorporated in Singapore, or a collective investment scheme constituted as a corporation) any or all of the shares in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing;
 - (c) a registered business trust (as defined in the Business Trusts Act (Cap. 31A)) any or all of the units in which are listed for quotation on the official list of a securities exchange;
 - (d) a recognised business trust any or all of the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing; or
 - (e) a collective investment scheme that is a trust, that invests primarily in real estate and real estaterelated assets specified by the Authority in the Code on Collective Investment Schemes, and any or all the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing ("Real Estate Investment Trust").
- 10. For further instructions and guidance on how to complete this notification form, please refer to section 6 of the User Guide on Electronic Notification Forms which can be accessed at the Authority's Internet website at http://www.mas.gov.sg (under "Regulations and Financial Stability", "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

Part I - General
Name of Listed Issuer:
Raffles Medical Group Ltd
Type of Listed Issuer:
✓ Company/Corporation Registered/Recognised Business Trust
Real Estate Investment Trust
Name of Director/CEO:
Lew Yoong Keong Allen
Is the Director/CEO also a substantial shareholder/unitholder of the Listed Issuer? — Yes
✓ No
Is the Director/CEO notifying in respect of his interests in securities of, or made available by, the Listed Issuer at the time of his appointment? Yes (Please proceed to complete Part II)
✓ No (Please proceed to complete Part III)
Date of notification to Listed Issuer:
26-Jun-2025

Part III - For an incumbent Director/CEO giving notice of an acquisition of, or a change in his interest in, securities of or made available by the Listed Issuer

ſ	24 San 2024
	24-Sep-2024
	Date on which Director/CEO became aware of the acquisition of, or change in, interest (if different from item 1 above, please specify the date):
	24-Sep-2024
	Explanation (if the date of becoming aware is different from the date of acquisition of, or change in, interest):
	Not applicable.
	Type of securities which are the subject of the transaction (more than one option may be
	chosen):
I	✓ Ordinary voting shares/units of Listed Issuer
	Other types of shares/units (excluding ordinary voting shares/units) of Listed Issuer
	Rights/Options/Warrants over shares/units of Listed Issuer
	Debentures of Listed Issuer
ļ	Rights/Options over debentures of Listed Issuer
	Contracts over shares of the Listed Issuer which Director/CEO is a party to, or under which he is entitled to a benefit, being contracts under which any person has a right to call for or to make delivery of shares in the Listed Issuer
ĺ	Participatory interests made available by Listed Issuer
	Others (please specify):
	Number of shares, units, rights, options, warrants, participatory interests and/or principa amount/value of debentures or contracts acquired or disposed of by Director/CEO:
	320,000 Options at S\$0.90 per share. Please refer to Company's announcement released on 2 September 2024.
	Amount of consideration paid or received by Director/CEO (excluding brokerage and stamp duties):
Ī	\$1.00 (consideration for the grant of Option)

7.	Circumstance giving rise to the interest or change in interest: Acquisition of: Securities via market transaction Securities via off-market transaction (e.g. married deals) Securities via physical settlement of derivatives or other securities Securities pursuant to rights issue Securities via a placement Securities via a placement Securities following conversion/exercise of rights, options, warrants or other convertibles Disposal of:
	Securities via market transaction
	Securities via off-market transaction (e.g. married deals)
	Other circumstances: Acceptance of employee share options/share awards Vesting of share awards Exercise of employee share options Acceptance of take-over offer for Listed Issuer Corporate action by Listed Issuer (please specify):
	Others (please specify):
0	Quantum of intercets in accurities hold by Director/CEO before and ofter the transaction

8. Quantum of interests in securities held by Director/CEO before and after the transaction. Please complete relevant table(s) below (for example, Table 1 should be completed if the change relates to ordinary voting shares of the Listed Issuer; Table 4 should be completed if the change relates to debentures):

Table 1. Change in respect of ordinary voting shares/units of Listed Issuer

Immediately before the transaction	Direct Interest	Deemed Interest	Total	
No. of ordinary voting shares/units held:	0 200,000		200,000	
As a percentage of total no. of ordinary voting shares/units:	0	0.011	0.011	
Immediately after the transaction	Direct Interest	Deemed Interest	Total	
No. of ordinary voting shares/units held:	0	200,000	200,000	

	0	0.011	0.011
As a percentage of total no. of ordinary voting shares/units:			

Table 3. Change in respect of rights/options/warrants over shares/units of Listed Issuer

Immediately before the transaction	Direct Interest	Deemed Interest	Total		
No. of rights/options/warrants held:	640,000 options	0	640,000 options		
No. (if known) of shares/units underlying the rights/options/ warrants:	640,000 ordinary shares	0	640,000 ordinary shares		
Immediately after the transaction	Direct Interest	Deemed Interest	Total		
Immediately after the transaction No. of rights/options/warrants held:	Direct Interest 960,000 options	Deemed Interest 0	Total 960,000 options		

9. Circumstances giving rise to deemed interests (if the interest is such): [You may attach a chart(s) in item 10 to illustrate how the Director/CEO's deemed interest, as set out in item 8 tables 1 to 8, arises]

Mr Lew's spouse, Ms Teo Lay Lam, holds 200,000 shares of Raffles Medical Group Ltd. Mr Lew is deemed to have an interest in the shares of Raffles Medical Group Ltd held by his spouse.

10. Attachments (if any): 🕥





(The total file size for all attachment(s) should not exceed 1MB.)

- If this is a **replacement** of an earlier notification, please provide: 11.
 - SGXNet announcement reference of the first notification which was announced on SGXNet (the "Initial Announcement"):

S	G	2	4	0	9	2	4	0	Т	Н	R	7	М	3	N
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

(b) Date of the Initial Announcement:

24-Sep-2024

15-digit transaction reference number of the relevant transaction in the Form 1 which was (c) attached in the Initial Announcement:

3 2 5 2 9	0 5 4	5 3 4	3 7 0 2
-----------	-------	-------	---------


12. Remarks (if any):

This notification is a replacement of the initial notification as stated in Item 11.

There was an error in Part III, Item 8, Table 1 of the initial notification, where it was disclosed that Mr Lew had a direct interest in 200,000 ordinary shares of Raffles Medical Group Ltd. The 200,000 ordinary shares are held under the name of Mr Lew's spouse, Ms Teo Lay Lam, and they are not held by Mr Lew. As such, Part III, Item 8, Table 1 and Part III, Item 9 have been amended to reflect the foregoing.

For the avoidance of doubt, the percentage level of Mr Lew's interest as set out in Part III, Item 8, Table 1 of this notification has been calculated on the basis of 1,858,101,925 ordinary shares in issue (excluding shares held in treasury and subsidiary holdings) as at 24 September 2024.

Transaction Reference Number (auto-generated):



Item 13 is to be completed by an individual submitting this notification form on behalf of the Director/CEO.

- 13. Particulars of Individual submitting this notification form to the Listed Issuer:
 - (a) Name of Individual:

Kimmy Goh

(b) Designation (if applicable):

Company Secretary

(c) Name of entity (if applicable):

Raffles Medical Group Ltd